在科特迪瓦共和国使用阿托伐醌-磺胺多辛治疗恶性疟原虫疟疾时早期治疗失败。
Early treatment failure during treatment of Plasmodium falciparum malaria with atovaquone-proguanil in the Republic of Ivory Coast.
机构信息
Unité de Parasitologie - Unité de Recherche pour les Maladies Infectieuses et Tropicales Emergentes - UMR 6236, Institut de Recherche Biomédicale des Armées, Marseille, France.
出版信息
Malar J. 2012 May 2;11:146. doi: 10.1186/1475-2875-11-146.
Abstract
The increased spread of drug-resistant malaria highlights the need for alternative drugs for treatment and chemoprophylaxis. The combination of atovaquone-proguanil (Malarone®) has shown high efficacy against Plasmodium falciparum with only mild side-effects. Treatment failures have been attributed to suboptimal dosages or to parasite resistance resulting from a point mutation in the cytochrome b gene. In this paper, a case of early treatment failure was reported in a patient treated with atovaquone-proguanil; this failure was not associated with a mutation in the parasite cytochrome b gene, with impaired drug bioavailability, or with re-infection.
摘要
耐多药疟疾的传播加剧，突显了寻找替代药物进行治疗和化学预防的必要性。阿托伐醌-磺胺多辛（复方阿莫地喹，商品名：科泰复）的组合对恶性疟原虫显示出高效，仅有轻微的副作用。治疗失败归因于剂量不足或由于细胞色素 b 基因突变导致寄生虫耐药。本文报告了 1 例用阿托伐醌-磺胺多辛治疗的患者出现早期治疗失败，该失败与寄生虫细胞色素 b 基因突变、药物生物利用度受损或再感染无关。
相似文献
1
Early treatment failure during treatment of Plasmodium falciparum malaria with atovaquone-proguanil in the Republic of Ivory Coast.在科特迪瓦共和国使用阿托伐醌-磺胺多辛治疗恶性疟原虫疟疾时早期治疗失败。
Malar J. 2012 May 2;11:146. doi: 10.1186/1475-2875-11-146.
2
Mutations in the Plasmodium falciparum cytochrome b gene are associated with delayed parasite recrudescence in malaria patients treated with atovaquone-proguanil.恶性疟原虫细胞色素b基因的突变与接受阿托伐醌-氯胍治疗的疟疾患者中寄生虫复发延迟有关。
Malar J. 2008 Nov 20;7:240. doi: 10.1186/1475-2875-7-240.
3
Failure of atovaquone-proguanil malaria chemoprophylaxis in a traveler to Ghana.前往加纳旅行者中阿托伐醌-磺胺多辛疟疾预防失败。
Travel Med Infect Dis. 2015 Jan-Feb;13(1):89-93. doi: 10.1016/j.tmaid.2014.12.010. Epub 2014 Dec 31.
4
Late clinical failure associated with cytochrome b codon 268 mutation during treatment of falciparum malaria with atovaquone-proguanil in traveller returning from Congo.旅行者从刚果返回后，使用阿托伐醌-磺胺多辛治疗恶性疟原虫疟疾时，第 268 密码子的细胞色素 b 突变与晚期临床失败相关。
Malar J. 2020 Jan 21;19(1):37. doi: 10.1186/s12936-020-3126-y.
5
In vitro atovaquone/proguanil susceptibility and characterization of the cytochrome b gene of Plasmodium falciparum from different endemic regions of Thailand.泰国不同疟疾流行地区恶性疟原虫的体外阿托伐醌/氯胍敏感性及细胞色素b基因特征
Malar J. 2008 Jan 28;7:23. doi: 10.1186/1475-2875-7-23.
6
Plasmodium falciparum malaria and atovaquone-proguanil treatment failure.恶性疟原虫疟疾与阿托伐醌-氯胍治疗失败
Emerg Infect Dis. 2008 Feb;14(2):320-2. doi: 10.3201/eid1402.070945.
7
Malarone treatment failure not associated with previously described mutations in the cytochrome b gene.甲氟喹治疗失败与先前描述的细胞色素b基因突变无关。
Malar J. 2004 Jun 8;3:14. doi: 10.1186/1475-2875-3-14.
8
Selection of Cytochrome Mutants Is Rare among Plasmodium falciparum Patients Failing Treatment with Atovaquone-Proguanil in Cambodia.在柬埔寨，阿托伐醌-磺胺多辛复方制剂治疗失败的疟原虫患者中，细胞色素突变体的选择很少见。
Antimicrob Agents Chemother. 2021 Feb 17;65(3). doi: 10.1128/AAC.01249-20.
9
Prolonged protection provided by a single dose of atovaquone-proguanil for the chemoprophylaxis of Plasmodium falciparum malaria in a human challenge model.阿托伐醌-磺胺多辛单剂在人体疟疾挑战模型中对恶性疟原虫疟疾的化学预防提供持久保护。
Clin Infect Dis. 2012 Jan 15;54(2):232-9. doi: 10.1093/cid/cir770. Epub 2011 Nov 3.
10
Screening for mutations related to atovaquone/proguanil resistance in treatment failures and other imported isolates of Plasmodium falciparum in Europe.在欧洲治疗失败的恶性疟原虫以及其他输入性分离株中筛查与阿托伐醌/氯胍耐药性相关的突变。
J Infect Dis. 2004 Nov 1;190(9):1541-6. doi: 10.1086/424469. Epub 2004 Sep 28.
引用本文的文献
1
Metal(triphenylphosphine)-atovaquone Complexes: Synthesis, Antimalarial Activity, and Suppression of Heme Detoxification.金属（三苯基膦）-阿托伐醌配合物：合成、抗疟活性及对血红素解毒的抑制作用
Inorg Chem. 2024 Sep 16;63(37):17087-17099. doi: 10.1021/acs.inorgchem.4c02751. Epub 2024 Aug 26.
2
[Epidemiology of malaria in the French Armed Forces].[法国武装部队中的疟疾流行病学]
Med Trop Sante Int. 2023 Feb 21;3(1). doi: 10.48327/mtsi.v3i1.2023.311. eCollection 2023 Mar 31.
3
Amplicon Deep Sequencing Reveals Multiple Genetic Events Lead to Treatment Failure with Atovaquone-Proguanil in Plasmodium falciparum.扩增子深度测序揭示多种遗传事件导致恶性疟原虫阿托伐醌-磺胺多辛治疗失败。
Antimicrob Agents Chemother. 2023 Jun 15;67(6):e0170922. doi: 10.1128/aac.01709-22. Epub 2023 May 8.
4
A mathematical model for the dynamics and control of malaria in Nigeria.尼日利亚疟疾动态与控制的数学模型
Infect Dis Model. 2022 Nov 5;7(4):728-741. doi: 10.1016/j.idm.2022.10.005. eCollection 2022 Dec.
5
Late clinical failure associated with cytochrome b codon 268 mutation during treatment of falciparum malaria with atovaquone-proguanil in traveller returning from Congo.旅行者从刚果返回后，使用阿托伐醌-磺胺多辛治疗恶性疟原虫疟疾时，第 268 密码子的细胞色素 b 突变与晚期临床失败相关。
Malar J. 2020 Jan 21;19(1):37. doi: 10.1186/s12936-020-3126-y.
6
Novel Mutation in Cytochrome B of Plasmodium falciparum in One of Two Atovaquone-Proguanil Treatment Failures in Travelers Returning From Same Site in Nigeria.在从尼日利亚同一地点返回的旅行者中，两种阿托伐醌-丙氧喹啉治疗失败的案例中，疟原虫细胞色素 B 出现新突变。
Open Forum Infect Dis. 2014 Aug 5;1(2):ofu059. doi: 10.1093/ofid/ofu059. eCollection 2014 Sep.
7
Molecular characterization of the cytochrome b gene and in vitro atovaquone susceptibility of Plasmodium falciparum isolates from Kenya.肯尼亚恶性疟原虫分离株细胞色素b基因的分子特征及阿托伐醌体外敏感性研究
Antimicrob Agents Chemother. 2015 Mar;59(3):1818-21. doi: 10.1128/AAC.03956-14. Epub 2015 Jan 12.
8
Artemether-lumefantrine compared to atovaquone-proguanil as a treatment for uncomplicated Plasmodium falciparum malaria in travelers.与阿托伐醌-氯胍相比，蒿甲醚-本芴醇用于治疗旅行者非复杂性恶性疟原虫疟疾的疗效比较。
Am J Trop Med Hyg. 2015 Jan;92(1):13-7. doi: 10.4269/ajtmh.14-0249. Epub 2014 Nov 4.
本文引用的文献
1
Vivax malaria in Mauritania includes infection of a Duffy-negative individual.毛里塔尼亚的间日疟包括对一个 Duffy 阴性个体的感染。
Malar J. 2011 Nov 3;10:336. doi: 10.1186/1475-2875-10-336.
2
[Atovaquone-proguanil treatment failure in Plasmodium falciparum].[阿托伐醌-氯胍治疗恶性疟原虫失败]
Presse Med. 2011 Nov;40(11):1081-3. doi: 10.1016/j.lpm.2011.03.009. Epub 2011 May 13.
3
Synergy of mefloquine activity with atorvastatin, but not chloroquine and monodesethylamodiaquine, and association with the pfmdr1 gene.甲氟喹与阿托伐他汀的协同作用，但氯喹和去乙基阿莫地喹无此作用，并与 pfmdr1 基因相关联。
J Antimicrob Chemother. 2010 Jul;65(7):1387-94. doi: 10.1093/jac/dkq173. Epub 2010 May 25.
4
Atorvastatin as a potential antimalarial drug: in vitro synergy in combinational therapy with dihydroartemisinin.阿托伐他汀作为一种潜在的抗疟药物：与双氢青蒿素联合治疗的体外协同作用。
Antimicrob Agents Chemother. 2010 Feb;54(2):966-7. doi: 10.1128/AAC.01006-09. Epub 2009 Nov 30.
5
Susceptibility of Plasmodium falciparum isolates to doxycycline is associated with pftetQ sequence polymorphisms and pftetQ and pfmdt copy numbers.疟原虫分离株对强力霉素的敏感性与 pftetQ 序列多态性以及 pftetQ 和 pfmdt 拷贝数有关。
J Infect Dis. 2010 Jan 1;201(1):153-9. doi: 10.1086/648594.
6
Sex affects the steady-state pharmacokinetics of primaquine but not doxycycline in healthy subjects.性别影响健康受试者中伯氨喹的稳态药代动力学，但不影响多西环素的稳态药代动力学。
Am J Trop Med Hyg. 2009 Nov;81(5):747-53. doi: 10.4269/ajtmh.2009.09-0214.
7
Plasmodium falciparum Na+/H+ exchanger 1 transporter is involved in reduced susceptibility to quinine.恶性疟原虫的钠/氢交换体1转运蛋白与对奎宁的敏感性降低有关。
Antimicrob Agents Chemother. 2009 May;53(5):1926-30. doi: 10.1128/AAC.01243-08. Epub 2009 Mar 9.
8
Atovaquone-proguanil resistance in imported falciparum malaria in a young child.一名幼儿输入性恶性疟原虫疟疾对阿托伐醌-氯胍耐药
Pediatr Infect Dis J. 2008 Jun;27(6):567-9. doi: 10.1097/INF.0b013e318167918d.
9
Plasmodium falciparum malaria and atovaquone-proguanil treatment failure.恶性疟原虫疟疾与阿托伐醌-氯胍治疗失败
Emerg Infect Dis. 2008 Feb;14(2):320-2. doi: 10.3201/eid1402.070945.
10
Possible autochthonous malaria from Marseille to Minneapolis.从马赛到明尼阿波利斯可能存在本地疟疾。
Emerg Infect Dis. 2007 Aug;13(8):1236-8. doi: 10.3201/eid1308.070143.
Zotero 插件